pramipexole has been researched along with Parkinson Disease, Secondary in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (50.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 3 (30.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bonastre, M; Fuentes, M; Marin, C; Mullol, J | 1 |
| da Costa, AN; Dardou, D; Dremier, S; Durif, F; Hafidi, A; Hanon, E; Loiodice, S; Ouachikh, O; Winlow, P | 1 |
| Akbartabar Touri, M; Delaviz, H; Ghavamzadeh, M; Jafari Barmak, M; Parishani, M; Sadeghi, H; Zarezade, V | 1 |
| Arami, MA; Ayromlou, H; Najmi, S | 1 |
| Anzellotti, F; Bonanni, L; D'Andreagiovanni, A; Di Iorio, A; Onofrj, M; Stocchi, F; Thomas, A; Varanese, S | 1 |
| Domino, EF; Kohno, Y; Ni, L; Sasa, M; Zhang, H | 2 |
| Bennett, JP; Cassarino, DS; Fall, CP; Smith, TS | 1 |
| Lorenc-Koci, E; Wolfarth, S | 1 |
| Mierau, J; Schingnitz, G | 1 |
1 trial(s) available for pramipexole and Parkinson Disease, Secondary
| Article | Year |
|---|---|
End-of-dose deterioration in non ergolinic dopamine agonist monotherapy of Parkinson's disease.
Topics: Benzothiazoles; Dopamine Agonists; Double-Blind Method; Endpoint Determination; Female; Humans; Indoles; Longitudinal Studies; Male; Middle Aged; Parkinson Disease; Parkinson Disease, Secondary; Pramipexole; Severity of Illness Index; Time Factors | 2006 |
9 other study(ies) available for pramipexole and Parkinson Disease, Secondary
| Article | Year |
|---|---|
Lack of correlation between dyskinesia and pallidal serotonin transporter expression-induced by L-Dopa and Pramipexole in hemiparkinsonian rats.
Topics: Animals; Disease Models, Animal; Dopamine Agonists; Dyskinesia, Drug-Induced; Globus Pallidus; Levodopa; Male; Oxidopamine; Parkinson Disease, Secondary; Pramipexole; Rats; Rats, Sprague-Dawley; Serotonin; Serotonin Plasma Membrane Transport Proteins; Signal Transduction | 2020 |
Pramipexole induced place preference after L-dopa therapy and nigral dopaminergic loss: linking behavior to transcriptional modifications.
Topics: alpha-Synuclein; Animals; Antiparkinson Agents; Benzothiazoles; Corpus Striatum; Dopamine; Female; Humans; Impulsive Behavior; Levodopa; Male; Parkinson Disease, Secondary; Pramipexole; Rats; Receptor, Metabotropic Glutamate 5 | 2017 |
Pramipexole reduces inflammation in the experimental animal models of inflammation.
Topics: Animals; Anti-Inflammatory Agents; Benzothiazoles; Carrageenan; Disease Models, Animal; Inflammation; Male; Mice; Parkinson Disease, Secondary; Pramipexole; Rats; Rats, Wistar; Tetradecanoylphorbol Acetate | 2017 |
Hemiparkinsonism-hemiatrophy syndrome.
Topics: Adult; Antiparkinson Agents; Atrophy; Benzothiazoles; Biperiden; Carbidopa; Cerebral Cortex; Cerebral Ventricles; Dopamine Agonists; Drug Combinations; Humans; Indans; Levodopa; Magnetic Resonance Imaging; Male; Monoamine Oxidase Inhibitors; Parkinson Disease, Secondary; Pramipexole; Tomography, X-Ray Computed | 2011 |
Talipexole or pramipexole combinations with chloro-APB (SKF 82958) in MPTP-induced hemiparkinsonian monkeys.
Topics: Animals; Antiparkinson Agents; Azepines; Basal Ganglia Diseases; Behavior, Animal; Benzazepines; Benzothiazoles; Dopamine Agents; Dopamine Agonists; Drug Interactions; Female; Macaca nemestrina; MPTP Poisoning; Parkinson Disease, Secondary; Pramipexole; Sleep; Thiazoles | 1997 |
Pramipexole reduces reactive oxygen species production in vivo and in vitro and inhibits the mitochondrial permeability transition produced by the parkinsonian neurotoxin methylpyridinium ion.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Antiparkinson Agents; Benzothiazoles; Biological Transport; Calcium; Corpus Striatum; Dopamine Agents; Humans; Ion Channel Gating; Liver; Male; Microdialysis; Mitochondria; Neuroblastoma; Neuroprotective Agents; Neurotoxins; Parkinson Disease, Secondary; Phosphorus; Porins; Pramipexole; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Thiazoles; Tumor Cells, Cultured | 1998 |
Effects of pramipexole on contraversive rotation and functional motor impairments in 1-methyl-4-phenyl1,2,3, 6-tetrahydropyridine-induced chronic hemiparkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Benzothiazoles; Dopamine Agents; Dose-Response Relationship, Drug; Eating; Female; Macaca nemestrina; Motor Activity; Parkinson Disease, Secondary; Pramipexole; Rotation; Stereotyped Behavior; Thiazoles; Volition | 1998 |
Efficacy of pramipexole, a new dopamine receptor agonist, to relieve the parkinsonian-like muscle rigidity in rats.
Topics: alpha-Methyltyrosine; Animals; Benzothiazoles; Dopamine Agonists; Dose-Response Relationship, Drug; Electromyography; Haloperidol; Male; Muscle Rigidity; Muscle, Skeletal; Parkinson Disease, Secondary; Pramipexole; Rats; Rats, Wistar; Reserpine; Thiazoles; Treatment Outcome | 1999 |
Biochemical and pharmacological studies on pramipexole, a potent and selective dopamine D2 receptor agonist.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Benzothiazoles; Corpus Striatum; Dihydroxyphenylalanine; Dopamine; Dopamine Agents; Dyskinesia, Drug-Induced; Exploratory Behavior; Female; Haloperidol; Male; Medial Forebrain Bundle; Mice; Motor Activity; Norepinephrine; Parkinson Disease, Secondary; Pramipexole; Rats; Receptors, Dopamine D2; Rotation; Stereoisomerism; Synapses; Thiazoles | 1992 |